Manufacturing a chimpanzee adenovirus‐vectored SARS‐CoV‐2 vaccine to meet global needs

• DOI: 10.1002/bit.27945
• Publication Date: 2021-09-29T21:19:27Z
• Authors: Carina C. D. Joe; Jinlin Jiang; Thomas Linke; Yuanyuan Li; Sofiya Fedosyuk; Gaurav Gupta; Adam Berg; Rameswara R. Segi...; David Mainwaring; Amar Joshi; Paul Cashen; Byron Rees; Nitin Chopra; Piergiuseppe Nestola; Jonathan Humphreys; Sarah Davies; Nick Smith; Scott Bruce; Dennis Verbart; Daan Bormans; Carol Knevelman; Mark Woodyer; Lee Davies; Lisa Cooper; Maria Kapanidou; Nicole Bleckwenn; Daniel Pappas; Teresa Lambe; Daniel C. Smith; Catherine M. Green; Raghavan Venkat; Adam J. Ritchie; Sarah C. Gilbert; Richard Turner; Alexander D. Douglas
• Keywords: Limiting; Manufacturing process; Pandemic; 2019-20 coronavirus outbreak

Abstract Manufacturing has been the key factor limiting rollout of vaccination during COVID‐19 pandemic, requiring rapid development and large‐scale implementation novel manufacturing technologies. ChAdOx1 nCoV‐19 (AZD1222, Vaxzevria) is an efficacious vaccine against SARS‐CoV‐2, based upon adenovirus vector. We describe a process for production this others same platform, including features to facilitate very production. discuss economics “distributed manufacturing” approach we have taken provide at globally‐relevant scale with international security supply. Together, these approaches enabled largest viral vector campaign date, providing substantial proportion global supply low cost.